Mer­ck KGaA takes its I/O op­tion on F-star Ther­a­peu­tics; Nephron spends $215M, eye­ing spot in Covid-19 vac­cine chain

5 years ago
News Briefing

Full Bril­in­ta study re­sults show the blood thin­ner re­duces rate of sec­ondary stroke

5 years ago
R&D

Gilead­'s ex-R&D chief Bischof­berg­er heads back to the biotech gi­ant to pick up a pair of late-stage drugs that had ...

5 years ago
Deals
R&D

The $1B Mer­ck-Bay­er drug that di­vid­ed car­di­ol­o­gists in March gets pri­or­i­ty re­view

5 years ago
R&D
FDA+

GSK’s Shin­grix leader Guil­laume Pfe­fer has jumped on board Flag­ship to helm a biotech hy­brid as Afeyan’s lat­est ...

5 years ago
People

An­ti­body leg­end Till­man Gern­gross is el­bow­ing his way in­to the Covid-19 R&D cru­sade: 'I don’t see this end­ing ...

5 years ago
Startups
Bioregnum

New biotech Exalys, seek­ing to pre­vent post­op­er­a­tive delir­i­um, launch­es with $15 mil­lion in Se­ries A

5 years ago
Financing
Startups

Covid-19 roundup: Rus­sia hack­ers tar­get US, UK vac­cine and drug re­searchers; Fau­ci fires back at White House cam­paign ...

5 years ago
Coronavirus

De­spite safe­ty, ef­fi­ca­cy con­cerns, FDA Ad­Com nar­row­ly rec­om­mends Mallinck­rodt drug

5 years ago
FDA+

A neu­ro­sur­geon spent the past 30 years de­vel­op­ing a neoanti­gen tu­mor vac­cine. Now he has $112M for a piv­otal test

5 years ago
Financing

Re­lay reaps $400M IPO wind­fall af­ter draw­ing the cur­tain on mo­tion-based drug de­sign pipeline

5 years ago
Financing

BioAt­la rakes in $72.5M Se­ries D, ad­vanc­ing re­search for pH-de­tect­ing can­cer treat­ments

5 years ago
Financing

A day af­ter Mod­er­na vac­cine re­sults, ru­mors swirl of pend­ing As­traZeneca da­ta

5 years ago
R&D
Coronavirus

Mil­li­pore­Sig­ma to build new $20 mil­lion, 12,000-square-foot lab in Switzer­land

5 years ago
R&D

Bio­haven re­cruits a Kar­dashi­an to help sell mi­graine drug; GSK li­cens­es lentivi­ral tech to Or­chard

5 years ago
News Briefing

‘Plan­ning to vac­ci­nate every­one in the US,’ Mod­er­na out­lines ef­forts to sup­ply their Covid-19 vac­cine as ...

5 years ago
Coronavirus

Who are the women blaz­ing trails in bio­phar­ma R&D and lead­ing the fight against Covid-19? Nom­i­nate them for ...

5 years ago
People
Editor's note

FDA rais­es ques­tions about Mallinck­rodt's HRS-1 drug be­fore ad­vi­so­ry hear­ing

5 years ago
FDA+

Ex­perts urge trans­paren­cy, ad­vi­so­ry com­mit­tee re­view for Covid-19 vac­cines

5 years ago
FDA+
Coronavirus

Gilead-part­nered Glympse snares $46.7M for their NASH-snoop­ing biosen­sors

5 years ago
Financing

FDA Ad­Com rec­om­mends GSK’s an­ti-BC­MA drug for ap­proval 12-0 de­spite sear­ing in-house re­view — does it mat­ter?

5 years ago
FDA+

Covid-19 roundup: Vac­cine by end of 2020? Ken Fra­zier warns hype do­ing 'grave dis­ser­vice'

5 years ago
Coronavirus

'Longevi­ty as a ser­vice': In­sil­i­co spins off AI biotech that trains deep learn­ing on an­ti-ag­ing treat­ments

5 years ago
Financing
R&D

NI­AID and Mod­er­na spell out a 'ro­bust' im­mune re­sponse in PhI coro­n­avirus vac­cine test — but big ques­tions re­main ...

5 years ago
R&D
Coronavirus
First page Previous page 822823824825826827828 Next page Last page
A service from the Financial Times